Verisk (NASDAQ:VRSK) Reports Q2 CY2026 In Line With Expectations

Verisk Analytics (NASDAQ:VRSK) reported Q2 CY2026 revenue of $806 million, up 4.3% year on year, matching Wall Street expectations, and adjusted EPS of $1.98, up from $1.88, beating consensus by 2.4%. For the full year, Verisk guided revenue to $3.22 billion at the midpoint and EPS to rise from $7.34 to $8.16, with shares down about 3% to $205.97 after the release.

Original reporting
Published Jul 29, 2026, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 1:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Verisk (NASDAQ:VRSK) Reports Q2 CY2026 In Line With Expectations — source image
Decision brief

The 30-second read

$VRSKNeutralMed
01

Why it matters

The key tradable inputs are the Q2 in-line revenue, the adjusted EPS beat, and the full-year guidance mix (revenue in line, EPS slightly missed), alongside the immediate ~3% post-report drop.

02

Market read

This is a guidance-and-earnings datapoint for VRSK, with a muted reaction suggesting investors were not surprised on topline but may have reacted to the guidance balance.

03

What to watch

The article highlights adjusted operating margin expansion to 46.9% and a shrinking share count (down 19.7%), which can offset modest revenue softness; traders may focus too narrowly on the guidance wording.

Relevance 7/10Novelty 6/10Timing: after-hours/immediate post-report reaction (stock down ~3% to $205.97)

Background

Verisk is an insurance data analytics provider processing billions of insurance transaction records annually, with results framed against Wall Street expectations.

Company-level read

Ticker impact

$VRSKNeutralMedium confidence
Context

Verisk reported Q2 CY2026 revenue of $806M (+4.3% YoY) and adjusted EPS $1.98, with full-year revenue guidance $3.22B midpoint.

Expected impact

Near-term bias neutral to slightly negative given the article notes the stock traded down about 3% after the report despite the EPS beat.

Evidence & confidence

The text provides a concrete earnings print (revenue, EPS, beat vs consensus) plus forward guidance (revenue in line, EPS guidance slightly missed) and an immediate post-report move (down ~3%).

Market effects

Provides a datapoint on business-services insurance analytics demand and operating leverage, but no explicit sector-wide catalyst.

No regional macro or FX shock beyond noting constant-currency growth aligned with reported growth.

Limited global relevance; the article frames results as in-line with expectations and does not cite international regulatory or competitive shocks.

Counterpoint

If investors underweight the margin expansion and share count reduction, the EPS trajectory (including expected full-year EPS growth) could support a rebound despite the initial selloff.

Key entities

  • Verisk Analytics

    Reported Q2 CY2026 revenue and adjusted EPS, plus full-year revenue and EPS guidance, and saw the stock drop ~3% immediately after reporting.

Related articles

$VRSKMedAI 8/10

Verisk Analytics (VRSK) Q2 2026 Earnings Call Transcript

Verisk Analytics (NASDAQ:VRSK) reported Q2 2026 revenue of $806 million, up 4.3% reported and 5.8% organic constant currency. Adjusted EBITDA was $464 million, up 7.4% on the same basis. Subscription revenue was 83% of total, and diluted adjusted EPS was $1.98. Full-year guidance was reaffirmed: revenue $3.19B to $3.24B and EPS $7.45 to $7.75.

$VRSKMedAI 8/10

Verisk Ordered to Move Ahead With $2.35 Billion AccuLynx Merger

A Delaware Chancery Court judge ordered Verisk Analytics to proceed with its $2.35 billion merger with AccuLynx, rejecting AccuLynx’s bid to raise the deal price over antitrust clearance concerns. The judge cited willful conduct by AccuLynx for a failed closing condition and awarded AccuLynx damages for direct costs plus interest. The deal still requires HSR Act clearance and FTC approval.

$VRSKMedAI 8/10

[VRSK Q2 2026 Earnings Call] Verisk Q2 Organic Revenue Hits 5.8% as XactAI Users Jump 10x to 7,000, but Transactional Drag Persists — BigGo Finance

Verisk Analytics (VRSK) reported Q2 2026 revenue of $806 million, up 5.8% organic constant currency, driven by 8% subscription growth (83% of revenue). Transactional revenue fell 4.2% due to softer commercial property quotes and weaker weather demand. XactAI users rose 10x to 7,000. Full-year guidance of $3.19–$3.24B revenue and $1.79–$1.83B adj. EBITDA was reaffirmed.

$VRSKMed

Verisk Vaults on Releasing Q2 Results

Verisk (NASDAQ: VRSK) reported Q2 results for the quarter ended June 30, 2026. Net income fell 9.8% to $229 million, citing higher tax rate, net interest expense, and legal fees tied to litigation. The company paid a $0.50 dividend per share and launched a $200 million accelerated share repurchase, with an initial delivery of 949,190 shares at $179.10. Shares rose 9.6% to $221.87.